{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:02:24Z","timestamp":1782536544645,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.chest.2024.07.168","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T22:28:09Z","timestamp":1724711289000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-2225","authenticated-orcid":false,"given":"Frank C.","family":"Sciurba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-2815","authenticated-orcid":false,"given":"Stephanie A.","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Rickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-0858","authenticated-orcid":false,"given":"Igor Z.","family":"Barjaktarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"116","key":"10.1016\/j.chest.2024.07.168_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1183\/09059180.00002610","article-title":"Impact of exacerbations on COPD","volume":"19","author":"Anzueto","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.chest.2024.07.168_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/COPD.S234942","article-title":"Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review","volume":"15","author":"Iheanacho","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2024.07.168_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.03.018","article-title":"The projected economic and health burden of sub-optimal asthma control in Canada","volume":"138","author":"Zafari","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2024.07.168_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/COPD.S36997","article-title":"Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population","volume":"7","author":"Pasquale","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.chest.2020.09.255","article-title":"Projecting long-term health and economic burden of COPD in the United States","volume":"159","author":"Zafari","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2024.07.168_bib8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2024.07.168_bib9","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"2014","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12931-018-0874-0","article-title":"Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT\u00ae trial","volume":"19","author":"Tashkin","year":"2018","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.chest.2024.07.168_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2024.07.168_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib14","doi-asserted-by":"crossref","first-page":"L59","DOI":"10.1152\/ajplung.00324.2015","article-title":"The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia","volume":"310","author":"Turner","year":"2016","journal-title":"Am J Physiol Lung\u00a0Cell Mol Physiol"},{"issue":"8","key":"10.1016\/j.chest.2024.07.168_bib15","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/sj.bjp.0703725","article-title":"The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways","volume":"131","author":"Schmidt","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bjp.0701792","article-title":"Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle","volume":"124","author":"Challiss","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2222.2011.03715.x","article-title":"Oxidative stress-induced glucocorticoid resistance is prevented by dual phosphodiesterase 3\/phosphodiesterase 4 inhibition in human alveolar macrophages","volume":"41","author":"Milara","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.chest.2024.07.168_bib18","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/COPD.S263025","article-title":"Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD: a detailed analysis","volume":"15","author":"Watz","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"10.1016\/j.chest.2024.07.168_bib19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease","volume":"198","author":"Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2024.07.168_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mcna.2018.12.005","article-title":"Chronic obstructive pulmonary disease: evaluation and management","volume":"103","author":"Duffy","year":"2019","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11606-009-0907-y","article-title":"The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations","volume":"24","author":"Au","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037509","article-title":"Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review","volume":"10","author":"Sonnex","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.chest.2024.07.168_bib25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2024.07.168_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/thoraxjnl-2012-202709","article-title":"Number needed to treat in COPD: exacerbations versus pneumonias","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2024.07.168_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/COPD.S410372","article-title":"Prognostic properties of the GOLD 2023 classification system","volume":"18","author":"Brat","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"10.1016\/j.chest.2024.07.168_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2024.07.168_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-019-1130-y","article-title":"Evaluation of exacerbations and blood eosinophils in UK and US COPD\u00a0populations","volume":"20","author":"Vogelmeier","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.chest.2024.07.168_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/COPD.S350167","article-title":"A\u00a0pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid","volume":"17","author":"Miravitlles","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.chest.2024.07.168_bib32","series-title":"IQVIA LAAD Patient Paid Claims Primary Indication Filter on: COPD - Acute, COPD - Maintenance From April 2020 to March 2022, Data on File","year":"2023"},{"key":"10.1016\/j.chest.2024.07.168_bib33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/COPD.S340794","article-title":"Treatment patterns for chronic obstructive pulmonary disease (COPD) in the United States: results from an observational cross-sectional physician and patient survey","volume":"17","author":"Mannino","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"10.1016\/j.chest.2024.07.168_bib34","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","article-title":"Pharmacologic management of chronic obstructive pulmonary disease. an official American Thoracic Society clinical practice guideline","volume":"201","author":"Nici","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.07.168_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","article-title":"Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review","volume":"23","author":"Hurst","year":"2022","journal-title":"Respir Res"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224049377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224049377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:04:35Z","timestamp":1762124675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224049377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0012369224049377"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.07.168","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.07.168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}